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A 56-year-old man presents to the emer-gency department with nausea, weak-
ness, and exertional dyspnea, which have 
been going on for 1 week. He is sent by his 
primary care physician after being noted to be 
hypotensive with a weak, thready pulse.
 He has had diarrhea with intermittent ab-
dominal pain over the past year, with 10 stools 
daily, including 3 or 4 at night. The stools are 
described as large, nonbloody, sticky, greasy, 
and occasionally watery. Stools are fewer 
when he curtails his food intake. The diarrhea 
is associated with occasional diffuse abdomi-
nal pain he describes as a burning sensation. 
He has no incontinence or tenesmus. He re-
ports that he has unintentionally lost 137 lb 
(62 kg) over the past year. He has not taken 
over-the-counter antidiarrheal agents.
 ■ CHRONIC DIARRHEA
1 Chronic diarrhea is defined as lasting for at least how long? 
 □ 1 week
 □ 2 weeks
 □ 3 weeks
 □ 4 weeks
Chronic diarrhea is defined as looser stools for 
more than 4 weeks,1 a period that allows most 
cases of acute, self-limited, infectious diarrhea 
to resolve. 
 Because individuals perceive diarrhea dif-
ferently, reported prevalence rates of chronic 
diarrhea vary.2 Based on the definition of hav-
ing excessive stool frequency, the prevalence 
in the United States is about 5%.1 
 In developing countries, the most common 
cause of chronic diarrhea is infection. In de-
veloped nations, irritable bowel syndrome, in-
flammatory bowel disease, malabsorption syn-
drome, and chronic infection predominate.1 
 Once chronicity is established, diarrhea 
should be characterized as inflammatory, fatty, 
or watery (Table 1).3 
 ■ CASE CONTINUED: 
HISTORY OF HYPERTENSION, DIABETES
Our patient reports that he has never traveled 
outside the United States. He has a history 
of hypertension and type 2 diabetes mellitus 
that is controlled on oral agents. He has had 
surgery for a radial fracture and for reconstruc-
tion of his knees. He uses no tobacco, alcohol, 
or illicit drugs and works as a train engineer. 
He has no pets. He knows of no family his-
tory of inflammatory bowel disease or chronic 
diarrhea.
 Comment. Patients with diabetes are at in-
creased risk of gastrointestinal problems, with 
severity increasing with poorer control.4 Al-
though our patient’s diabetes puts him at risk of 
diabetic autonomic neuropathy, his blood glu-
cose control has been consistently good since 
his diagnosis, and his last measured hemoglo-
bin A1c was 7.3% (reference range 4%–7%). 
His description of greasy stools in conjunction 
with his marked weight loss puts fatty diarrhea 
higher on the differential diagnosis.
 ■ DRUG-INDUCED DIARRHEA
His medications include glimepiride 1 mg 
twice daily, lisinopril 10 mg daily, metformin 
500 mg twice daily, omeprazole 40 mg daily, 
and naproxen 220 mg daily. He has been tak-
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ing metformin for at least 2 years. He is aller-
gic to pentobarbital.
2 Which of his medications is least likely to be associated with his diarrhea? 
 □ Lisinopril
 □ Metformin
 □ Glimepiride
 □ Naproxen
More than 700 drugs are known to cause 
diarrhea, often through the interplay of si-
multaneous mechanisms.5 The diagnosis of 
drug-induced diarrhea requires taking a care-
ful medication history and establishing a tem-
poral relationship between the drug and the 
diarrheal symptoms. Treatment consists of 
withdrawing the offending agent. 
 Nonsteroidal anti-inflammatory drugs (eg, 
naproxen) are associated with collagenous 
colitis that occurs mostly after long-term use 
(> 6 months). Metformin-induced diarrhea is 
related to fat malabsorption.5 Olmesartan, an 
angiotensin II receptor antagonist, has been 
associated with severe sprue-like enteropa-
thy.6 On the other hand, the incidence of di-
arrhea with lisinopril is similar to that with 
placebo.7 
 ■ CASE CONTINUED: 
EXAMINATION AND LABORATORY VALUES
The patient’s primary care physician had re-
cently referred him to a gastroenterologist, 
and 4 days before presenting to the emergency 
department he had undergone abdominal and 
TABLE 1
Characteristics of diarrheal types
Diarrheal type Pathophysiology Clinical features Common causes Testing
Inflammatory Inflamed  
mucosa
Small-volume, bloody 
stools
Associated tenesmus
Abdominal pain  
and possibly fever
Infection
Inflammatory bowel 
disease
Ischemia
Radiation
Stool leukocytes
Direct visualization 
and biopsy of mucosa 
with flexible sigmoidoscopy 
or colonoscopy
Fatty Malabsorption, 
maldigestion
Weight loss
Bulky, greasy, sticky 
stools
Celiac disease
Pancreatic exocrine 
insufficiency
Small-bowel intestinal 
bacterial overgrowth
Sudan stain for fat in stool
Small-bowel biopsy
Pancreatic imaging
Hydrogen breath testing
Watery Osmotic Watery stools 
that improve 
with fasting
Lactose intolerance
Laxative ingestion
Fecal osmotic gap > 50 mmol/L
Stool pH < 6 with 
carbohydrate malabsorption
Colonoscopy
Secretory Watery stools,  
no change with fasting
Infection
Inflammatory bowel 
disease
Bile acid malabsorption
Post-vagotomy
Diabetic neuropathy
Endocrine tumors
Fecal osmotic gap < 50 mmol/L
Colonoscopy
Endocrine testing  
if supporting signs and  
symptoms are present
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pelvic computed tomography (CT) with io-
dinated contrast, which had showed hepatic 
steatosis and pancreatic atrophy.
 On examination now, the patient’s tem-
perature is 97.5°F (36.4°C), heart rate 90 
beats per minute, respirations 18 breaths per 
minute, oxygen saturation 99% on room air, 
and blood pressure 85/55 mm Hg. His body 
mass index is 32.5 kg/m2. His oral mucosa is 
dry. The rest of the examination is normal. No 
rash or ulcers are noted.
 His laboratory values (Table 2) are no-
table for sodium 130 mmol/L, potassium 2.2 
mmol/L, bicarbonate 9 mmol/L, blood urea 
nitrogen 32 mg/dL, creatinine 4.18 mg/dL, 
and international normalized ratio 5.4. Arte-
rial blood gases drawn on admission reveal pH 
7.32 and pCO2 19 mm Hg. 
 ■ ACID-BASE DISTURBANCES 
3 The patient’s acidosis is most likely related to which of the following? 
 □ Sepsis
 □ Diarrhea
 □ Metformin
 □ Acute kidney injury
It is most likely related to diarrhea. The pa-
tient has a non-anion-gap metabolic acidosis. 
(The anion gap can be calculated by subtract-
ing the sum of the serum bicarbonate and 
chloride values from the sodium—here, 130 – 
[112 + 9] = 9—and most textbooks list the ref-
erence range as 10–12 mmol/L.) Non-anion-
gap metabolic acidosis results from excessive 
loss of bicarbonate or impaired ability of the 
kidney to excrete acid. Bicarbonate losses can 
occur in diarrhea or in ureteral diversion to 
the colon. Impairment in urinary acidification 
can occur in renal tubular acidosis. 
 To determine the cause of non-anion-gap 
acidosis, calculating the urine anion gap can 
be useful (Table 3), as it reflects the ability of 
the kidneys to excrete acid and is an indirect 
measure of ammonium excretion. Our pa-
tient’s urine anion gap is –45 mmol/L ([62 + 
8] – 115), which supports diarrhea as the cause 
of his non-anion-gap acidosis. Sepsis, metfor-
min use, or acute kidney injury would result in 
an anion-gap acidosis.
 To manage acid-base disturbances, it is 
important to first determine whether there is 
a single primary disturbance with compensa-
tion or a mixed disorder. In the case of meta-
bolic acidosis, for every 1-mmol/L decrease in 
bicarbonate, there should be a corresponding 
1.3-mm Hg decrease in pCO2. Our patient’s 
laboratory data show that he had a pure non-
anion-gap metabolic acidosis.8 His sensation 
of dyspnea was likely related to respiratory 
compensation as evidenced by an appropri-
ately low pCO2. 
TABLE 2
Our patient’s laboratory results 
Test
4 days 
before 
admission
On  
admission
Reference 
range
Sodium (mmol/L) 130 135–146
Potassium (mmol/L) 2.2 3.5–5.0
Chloride (mmol/L) 112 98–110
Bicarbonate (mmol/L) 9 23–32
Blood urea nitrogen (mg/dL) 16 32 10–25
Creatinine (mg/dL 1.3 4.18 0.70–1.40
Glucose (mg/dL) 209 —
Calcium (mg/dL) 8.7 8.5–10.5
Magnesium (mg/dL) 1.5 1.7–2.6
Phosphorus (mg/dL) 2.5 2.5–4.5
Alanine aminotransferase (U/L) 68 5–50
Aspartate aminotransferase (U/L) 65 7–40
Total bilirubin (mg/dL) 0.8 0–1.5
Albumin (g/dL) 3.4 3.5–5.5
International normalized ratio 5.4 0.8–1.2
White blood cell count (× 109/L) 13.6 3.7–11.0
Hemoglobin (g/dL) 16.4 13.0–17.0
Platelet count (× 109/L) 254 150–400
pH 7.32 7.32–7.42
pCO2 (mm Hg) 19 42–55
Urine studies
Sodium (mmol/L) 62 14–216
Potassium (mmol/L 8 0–160
Chloride (mmol/L) 115 16–250
Creatinine (mg/dL) 59 20–300
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 ■ CASE CONTINUED: 
HIS LABORATORY VALUES IMPROVE
The patient is admitted to the hospital for 
fluid resuscitation with normal saline and po-
tassium and magnesium replacement. 
 Renal ultrasonography reveals normal-
appearing kidneys without obstruction. The 
calculated fractional excretion of sodium is 
3.4%. Urine microscopy reveals two to five 
hyaline casts per low-power field. His urine 
output remains adequate, and 3 days after 
hospitalization, his renal function starts to 
improve, as reflected in falling serum creati-
nine and blood urea nitrogen levels: his cre-
atinine level has declined to 1.91 mg/dL and 
his blood urea nitrogen level has declined 
to 24 mg/dL. His acute kidney injury is at-
tributed to intravenous contrast given for 
computed tomography, as well as to volume 
depletion and hypotension. 
 Stool studies for ova, parasites, and Clos-
tridium difficile are negative. Fecal calprotectin 
and lactoferrin are useful noninvasive mark-
ers of intestinal inflammation9 but were not 
checked in this case.
 Loperamide, taken as needed, is started 
for his diarrhea, along with empiric pancre-
atic enzyme replacement. After 3 days of 
treatment with oral vitamin K 10 mg, his in-
ternational normalized ratio comes down to 
1.4, from his admission value of 5.4. Given 
the clinical concern for fat malabsorption, 
vitamin D levels are also checked: his 25-hy-
droxyvitamin D level is less than 10 ng/mL 
(lower limit of normal 20). His fecal neutral 
fats are reported as normal, but split fats are 
increased.
 ■ STOOL FAT STUDIES
4 What does increased fecal split fats but normal fecal neutral fats imply?
 □ Pancreatic insufficiency
 □ Intestinal malabsorption
 □ Does not differentiate between the two
The finding does not differentiate between 
pancreatic insufficiency and intestinal malab-
sorption. The two-step Sudan stain has been 
used to differentiate maldigestion (eg, caused 
by pancreatic insufficiency) from malabsorp-
tion. Although patients with impaired diges-
tion were once thought to excrete excessive 
amounts of intact triglyceride whereas those 
with malabsorption excrete more of the lipo-
lytic or “split” product, the Sudan stain does 
not differentiate between the two.10 Stool 
fecal-elastase 1 testing correlates well with 
pancreatic exocrine function but was not per-
formed in our patient.11
 ■ CASE CONTINUED: 
CELIAC DISEASE IS DIAGNOSED
Given the description of his stools, uninten-
tional weight loss, and improvement of stool 
frequency with fasting, serologic testing for ce-
liac disease is performed (Table 4). The patient 
undergoes esophagogastroduodenoscopy, which 
shows mild duodenitis. Small-bowel biopsy re-
veals blunted villous architecture and increased 
mixed inflammatory cells of the epithelium and 
lamina propria, suggestive of celiac disease. 
 The patient is diagnosed with celiac dis-
ease and is counseled to follow a gluten-free 
diet. He is discharged home and scheduled to 
follow up with a gastroenterologist and ne-
phrologist. His liver function test abnormali-
ties are attributed to a combination of nonal-
coholic steatohepatitis and celiac disease.
 ■ CELIAC DISEASE  
AND MALABSORPTION
Celiac disease is an immune-mediated disor-
der that causes mucosal injury to the small 
intestine, leading to malabsorption. It is trig-
gered by gluten intake in genetically suscep-
tible individuals. The HLA-DQ2 haplotype is 
expressed in nearly 90% of patients with the 
disease. 
Most  
cases of  
self-limited  
diarrhea  
resolve 
in 4 weeks
TABLE 3
Urine anion gap 
The urine anion gap is calculated from urine 
laboratory values as follows: 
Anion gap = (sodium + potassium) – chloride 
Results 
Negative anion gap: gastrointestinal losses 
Positive anion gap: renal acid excretion
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 The worldwide prevalence of celiac disease 
is about 0.6% to 1%. Those with an affected 
first-degree relative, type 1 diabetes, Hashimo-
to thyroiditis, an autoimmune disease, Down 
syndrome, Turner syndrome, or IgA deficiency 
have an increased risk. 
 Celiac disease presents with chronic diar-
rhea, weight loss, and abdominal distention 
and pain. Sequelae of nutrient malabsorption 
such as iron-deficiency anemia, short stature, 
and osteopenia may be evident. Liver function 
may also be impaired. Dermatitis herpetifor-
mis and gluten ataxia are rarer presentations 
of celiac disease.12 
 In the absence of immunoglobulin (Ig) A 
deficiency, measurement of serum IgA anti- 
tissue transglutaminase antibodies is recom-
mended for initial testing. IgG antitissue 
transglutaminase antibodies can be measured 
in those with IgA deficiency.12 
 Duodenal biopsies to confirm the diagnosis 
are recommended in adults unless they have 
previously had biopsy-proven dermatitis her-
petiformis. 
Gluten-free diet
The treatment for celiac disease is avoidance 
of gluten. Patients who consult with a nutri-
tionist and participate in an advocacy group 
are more likely to adhere to a gluten-free diet, 
and the physician should strongly encourage 
and facilitate these activities.13 
 Untreated disease can lead to osteoporo-
sis, impaired splenic function with increased 
risk of infection with encapsulated organisms, 
infertility or recurrent abortion, ulcerative je-
junoileitis, and lymphoma.12 Patients should 
be monitored annually for adherence to the 
gluten-free diet and for the development of 
any associated condition. Despite adherence 
to a gluten-free diet, calcium absorption and 
bone mineral density are lower in patients 
with celiac disease than in controls.14 Care-
ful monitoring of fracture risk and adequate 
calcium and vitamin D replacement are also 
important. 
 Our patient undergoes dual-emission x-ray 
absorptiometry after discharge, with results 
consistent with osteopenia. His T scores range 
from –0.2 at the right hip to –1.1 in the left 
femoral neck. 
 Recurrence or persistently abnormal levels 
of IgA anti-tissue transglutaminase antibodies 
usually indicates poor dietary compliance.12
5 In patients whose symptoms do not im-prove on gluten restriction, there should 
be concern for which of the following?
 □ Lymphoma
 □ Nonadherence to gluten restriction
 □ Microscopic colitis
 □ All of the above
The answer is all of the above. Up to 30% of 
patients have persistent symptoms on a gluten-
free diet. Persistent exposure to gluten is the 
most common reason for lack of clinical im-
provement. In addition, bacterial overgrowth 
of the small bowel, lactose intolerance, pan-
creatic insufficiency, and microscopic colitis 
may coexist with celiac disease and may con-
tribute to ongoing symptoms. In a small subset 
of patients with persistent villous atrophy and 
symptoms despite strict adherence to a gluten-
free diet for 12 months, the disease is deemed 
“refractory.” Refractory celiac disease can be 
a precursor to enteropathy-associated T-cell 
lymphoma.13
 ■ CASE CONCLUDED
On telephone follow-up 3 weeks after dis-
charge, the patient reports complete resolu-
tion of diarrhea and stabilization of his weight. 
He reports strict adherence to a gluten-free 
diet and feels he is coping well.
Diagnoses
• Presenting weakness secondary to dehy-
dration and hypokalemia
• Dyspnea secondary to respiratory compen-
sation for metabolic acidosis
• Non-anion-gap metabolic acidosis second-
Greasy stools 
and marked 
weight loss 
make fatty  
diarrhea  
more likely
TABLE 4
Results of serologic testing
Test Result
Reference 
range
Celiac endomysial IgA Positive
Celiac gliadin IgA (EU/mL) 102 < 6.1
Celiac gliadin IgG (EU/mL) 51 < 4.9
Celiac tissue transglutaminase  IgA (U/mL) 94 < 10.3
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ary to diarrhea
• Acute kidney injury secondary to iodin-
ated contrast, volume depletion, hypoten-
sion
• Chronic diarrhea secondary to celiac dis-
ease
• Coagulopathy secondary to fat malabsorp-
tion secondary to celiac disease.	 ■
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